Preload Image
Preload Image
Report Store mobile icon
Global Immune Checkpoint Blockers Market Growth 2024-2030

Global Immune Checkpoint Blockers Market Growth 2024-2030

2024

Global Immune Checkpoint Blockers Market Growth 2024-2030

The global Immune Checkpoint Blockers market was valued at US$ 17.37 billion in 2024, driven by demand in cancer immunotherapy and other related treatments.

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global immune checkpoint blockers market is experiencing significant growth due to the increasing prevalence of various types of cancer and the rising demand for advanced immunotherapies. Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment landscape for cancers by stimulating the body's immune system to target and destroy cancer cells. These inhibitors work by blocking the immune checkpoints, which are the natural mechanisms that regulate the immune system and prevent overactive immune responses. Under normal circumstances, checkpoints such as PD-1, PD-L1, and CTLA-4 act as brakes on the immune system to prevent it from attacking normal cells. However, cancer cells often exploit these checkpoints to evade detection and destruction by the immune system. Immune checkpoint blockers aim to interfere with this process, effectively allowing the immune system to recognize and attack the cancer cells. The approval of these therapies for treating cancers such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others has significantly expanded the market. Furthermore, the success of ICIs in clinical trials has prompted increased investments in research and development, driving further innovation in this space. Pharmaceutical companies are working on improving the efficacy, safety profiles, and patient outcomes associated with immune checkpoint inhibitors. The market is being driven by the growing understanding of cancer biology, the increased focus on personalized medicine, and the rise of combination therapies. These factors, along with advancements in genomic sequencing and biomarker identification, have enabled the development of targeted therapies that are tailored to individual patients based on their unique cancer profiles. In addition to oncology, immune checkpoint inhibitors are also being explored for treating a range of other diseases, including autoimmune disorders and infectious diseases, further expanding the market's potential. As these therapies continue to gain acceptance and approval from regulatory authorities, the immune checkpoint blockers market is expected to grow at an accelerated pace, offering hope to cancer patients and other individuals suffering from complex diseases.

According to Publisher, the global Immune Checkpoint Blockers market size was valued at US$ 17370 million in 2024. With growing demand in downstream market, the Immune Checkpoint Blockers is forecast to a readjusted size of US$ 54080 million by 2030 with a CAGR of 17.6% during review period. The market for immune checkpoint blockers is primarily segmented based on the types of inhibitors, therapeutic areas, and geographical regions. By type, the market is dominated by PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors. Among these, PD-1 inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have gained significant traction due to their effectiveness in treating a wide range of cancers. These inhibitors work by blocking the interaction between the PD-1 receptor on T cells and its ligand PD-L1, which is often overexpressed by cancer cells. By blocking this interaction, PD-1 inhibitors enable T cells to effectively recognize and destroy cancer cells. PD-L1 inhibitors, including atezolizumab (Tecentriq) and durvalumab (Imfinzi), are also gaining popularity, particularly in the treatment of non-small cell lung cancer and urothelial carcinoma. CTLA-4 inhibitors, such as ipilimumab (Yervoy), were among the first immune checkpoint inhibitors to be approved and are often used in combination with PD-1 inhibitors to enhance the overall immune response against tumors. The combination of PD-1 and CTLA-4 inhibitors has shown promising results in clinical trials, particularly in melanoma and renal cell carcinoma, leading to a surge in combination therapy-based treatment protocols. Geographically, North America, particularly the United States, holds the largest share of the immune checkpoint blockers market due to the presence of leading pharmaceutical companies, well-established healthcare infrastructure, and high healthcare spending. The approval of several ICIs by the U.S. Food and Drug Administration (FDA) has played a crucial role in the growth of the market in this region. Additionally, Europe and Asia-Pacific are emerging as key markets due to the growing incidence of cancer, increased healthcare investments, and advancements in medical research. The availability of affordable cancer treatments in emerging economies, combined with increasing awareness and healthcare accessibility, is further fueling the growth of the immune checkpoint blockers market in these regions. With the expansion of clinical indications, ongoing clinical trials, and the potential to treat more types of cancer, the global immune checkpoint blockers market is expected to witness sustained growth in the coming years.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The segmentation of the immune checkpoint blockers market by therapeutic area highlights the diverse range of applications for these treatments, primarily focusing on oncology. Cancer remains the dominant therapeutic area for immune checkpoint inhibitors, with significant advancements in treating various types of tumors. Immune checkpoint blockers have been most successful in the treatment of melanoma, where they have demonstrated impressive results in terms of improving survival rates. The approval of pembrolizumab and nivolumab has transformed the treatment paradigm for advanced melanoma, providing patients with long-lasting remission possibilities. Similarly, the use of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) has led to groundbreaking improvements in survival outcomes. PD-1 and PD-L1 inhibitors have become standard treatments for advanced or metastatic NSCLC, and ongoing research is exploring their use in earlier stages of the disease. Other cancers, such as renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, and Hodgkin lymphoma, are also being effectively treated with ICIs, leading to improved patient survival and quality of life. The potential of immune checkpoint inhibitors to treat cancers with low mutational burdens, such as pancreatic and ovarian cancers, is also being explored, though challenges remain in these areas. Outside of oncology, immune checkpoint inhibitors are gaining attention in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus, as well as in infectious diseases, including chronic viral infections like hepatitis B and HIV. While still in the experimental phase, these indications hold significant promise for expanding the therapeutic applications of immune checkpoint blockers beyond cancer. Researchers are also investigating the potential of combining ICIs with other treatment modalities, such as chemotherapy, targeted therapies, and radiation therapy, to improve the efficacy of treatment protocols and reduce potential side effects. As the therapeutic indications for immune checkpoint blockers continue to expand, the market is expected to experience growth not only in oncology but also in other therapeutic areas where these drugs can help modulate the immune system to achieve better clinical outcomes.

The immune checkpoint blockers market is also segmented based on the types of patients treated and the stage of cancer at which treatment is administered. Immune checkpoint inhibitors are commonly used in both early and late stages of cancer, though their effectiveness tends to be more pronounced in advanced stages. In the early stages, ICIs are often used in combination with other therapies, such as chemotherapy or radiation, to achieve better treatment outcomes. For example, in early-stage melanoma and NSCLC, immune checkpoint inhibitors are being explored as part of adjuvant therapy to prevent cancer recurrence and improve long-term survival. In late-stage or metastatic cancers, ICIs are used as a monotherapy or in combination with other immunotherapies to manage disease progression and extend survival. As the efficacy of immune checkpoint blockers continues to improve, the market is likely to see a growing shift toward earlier-stage cancer treatment. Another key segmentation factor is the type of cancer, with different ICIs being more effective for specific cancer types. In the case of melanoma, nivolumab and pembrolizumab have demonstrated significant clinical success, while in NSCLC, both PD-1 and PD-L1 inhibitors have become first-line treatments. Other cancer types, such as renal cell carcinoma, liver cancer, and ovarian cancer, are also benefiting from the use of immune checkpoint inhibitors, though further clinical studies are needed to optimize treatment protocols for these cancers. The development of personalized medicine and companion diagnostics is further shaping the market, enabling healthcare providers to select the most appropriate immune checkpoint inhibitor for each patient based on their genetic and molecular profile. With continued advancements in the understanding of cancer biology and immune system interactions, the immune checkpoint blockers market is likely to see continued expansion and innovation across multiple therapeutic areas.


Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Immune Checkpoint Blockers Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Immune Checkpoint Blockers by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Immune Checkpoint Blockers by Country/Region, 2019, 2023 & 2030
  • 2.2 Immune Checkpoint Blockers Segment by Type
  • 2.2.1 Anti-PD-L1 Drug
  • 2.2.2 Anti-PD-1 Drug
  • 2.2.3 CTLA4
  • 2.3 Immune Checkpoint Blockers Sales by Type
  • 2.3.1 Global Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Immune Checkpoint Blockers Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Immune Checkpoint Blockers Sale Price by Type (2019-2024)
  • 2.4 Immune Checkpoint Blockers Segment by Application
  • 2.4.1 Lung Cancer
  • 2.4.2 Colorectal Cancer
  • 2.4.3 BreastCancer
  • 2.4.4 Prostate Cancer
  • 2.4.5 Melanoma
  • 2.4.6 Blood Cancers
  • 2.5 Immune Checkpoint Blockers Sales by Application
  • 2.5.1 Global Immune Checkpoint Blockers Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Immune Checkpoint Blockers Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Immune Checkpoint Blockers Sale Price by Application (2019-2024)
  • 3 Global Immune Checkpoint Blockers by Company
  • 3.1 Global Immune Checkpoint Blockers Breakdown Data by Company
  • 3.1.1 Global Immune Checkpoint Blockers Annual Sales by Company (2019-2024)
  • 3.1.2 Global Immune Checkpoint Blockers Sales Market Share by Company (2019-2024)
  • 3.2 Global Immune Checkpoint Blockers Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Immune Checkpoint Blockers Revenue by Company (2019-2024)
  • 3.2.2 Global Immune Checkpoint Blockers Revenue Market Share by Company (2019-2024)
  • 3.3 Global Immune Checkpoint Blockers Sale Price by Company
  • 3.4 Key Manufacturers Immune Checkpoint Blockers Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Immune Checkpoint Blockers Product Location Distribution
  • 3.4.2 Players Immune Checkpoint Blockers Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Immune Checkpoint Blockers by Geographic Region
  • 4.1 World Historic Immune Checkpoint Blockers Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Immune Checkpoint Blockers Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Immune Checkpoint Blockers Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Immune Checkpoint Blockers Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Immune Checkpoint Blockers Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Immune Checkpoint Blockers Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Immune Checkpoint Blockers Sales Growth
  • 4.4 APAC Immune Checkpoint Blockers Sales Growth
  • 4.5 Europe Immune Checkpoint Blockers Sales Growth
  • 4.6 Middle East & Africa Immune Checkpoint Blockers Sales Growth
  • 5 Americas
  • 5.1 Americas Immune Checkpoint Blockers Sales by Country
  • 5.1.1 Americas Immune Checkpoint Blockers Sales by Country (2019-2024)
  • 5.1.2 Americas Immune Checkpoint Blockers Revenue by Country (2019-2024)
  • 5.2 Americas Immune Checkpoint Blockers Sales by Type
  • 5.3 Americas Immune Checkpoint Blockers Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Immune Checkpoint Blockers Sales by Region
  • 6.1.1 APAC Immune Checkpoint Blockers Sales by Region (2019-2024)
  • 6.1.2 APAC Immune Checkpoint Blockers Revenue by Region (2019-2024)
  • 6.2 APAC Immune Checkpoint Blockers Sales by Type
  • 6.3 APAC Immune Checkpoint Blockers Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Immune Checkpoint Blockers by Country
  • 7.1.1 Europe Immune Checkpoint Blockers Sales by Country (2019-2024)
  • 7.1.2 Europe Immune Checkpoint Blockers Revenue by Country (2019-2024)
  • 7.2 Europe Immune Checkpoint Blockers Sales by Type
  • 7.3 Europe Immune Checkpoint Blockers Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Immune Checkpoint Blockers by Country
  • 8.1.1 Middle East & Africa Immune Checkpoint Blockers Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Immune Checkpoint Blockers Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Immune Checkpoint Blockers Sales by Type
  • 8.3 Middle East & Africa Immune Checkpoint Blockers Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Blockers
  • 10.3 Manufacturing Process Analysis of Immune Checkpoint Blockers
  • 10.4 Industry Chain Structure of Immune Checkpoint Blockers
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Immune Checkpoint Blockers Distributors
  • 11.3 Immune Checkpoint Blockers Customer
  • 12 World Forecast Review for Immune Checkpoint Blockers by Geographic Region
  • 12.1 Global Immune Checkpoint Blockers Market Size Forecast by Region
  • 12.1.1 Global Immune Checkpoint Blockers Forecast by Region (2025-2030)
  • 12.1.2 Global Immune Checkpoint Blockers Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Immune Checkpoint Blockers Forecast by Type
  • 12.7 Global Immune Checkpoint Blockers Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Bristol Myers Squibb
  • 13.1.1 Bristol Myers Squibb Company Information
  • 13.1.2 Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolios and Specifications
  • 13.1.3 Bristol Myers Squibb Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Bristol Myers Squibb Main Business Overview
  • 13.1.5 Bristol Myers Squibb Latest Developments
  • 13.2 Merck
  • 13.2.1 Merck Company Information
  • 13.2.2 Merck Immune Checkpoint Blockers Product Portfolios and Specifications
  • 13.2.3 Merck Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 Merck Main Business Overview
  • 13.2.5 Merck Latest Developments
  • 13.3 AstraZeneca
  • 13.3.1 AstraZeneca Company Information
  • 13.3.2 AstraZeneca Immune Checkpoint Blockers Product Portfolios and Specifications
  • 13.3.3 AstraZeneca Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 AstraZeneca Main Business Overview
  • 13.3.5 AstraZeneca Latest Developments
  • 13.4 Roche
  • 13.4.1 Roche Company Information
  • 13.4.2 Roche Immune Checkpoint Blockers Product Portfolios and Specifications
  • 13.4.3 Roche Immune Checkpoint Blockers Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Roche Main Business Overview
  • 13.4.5 Roche Latest Developments
  • 14 Research Findings and Conclusion


Table 1. Immune Checkpoint Blockers Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Immune Checkpoint Blockers Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Anti-PD-L1 Drug
Table 4. Major Players of Anti-PD-1 Drug
Table 5. Major Players of CTLA4
Table 6. Global Immune Checkpoint Blockers Sales by Type (2019-2024) & (K Units)
Table 7. Global Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Table 8. Global Immune Checkpoint Blockers Revenue by Type (2019-2024) & ($ million)
Table 9. Global Immune Checkpoint Blockers Revenue Market Share by Type (2019-2024)
Table 10. Global Immune Checkpoint Blockers Sale Price by Type (2019-2024) & (USD/Unit)
Table 11. Global Immune Checkpoint Blockers Sales by Application (2019-2024) & (K Units)
Table 12. Global Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Table 13. Global Immune Checkpoint Blockers Revenue by Application (2019-2024)
Table 14. Global Immune Checkpoint Blockers Revenue Market Share by Application (2019-2024)
Table 15. Global Immune Checkpoint Blockers Sale Price by Application (2019-2024) & (USD/Unit)
Table 16. Global Immune Checkpoint Blockers Sales by Company (2019-2024) & (K Units)
Table 17. Global Immune Checkpoint Blockers Sales Market Share by Company (2019-2024)
Table 18. Global Immune Checkpoint Blockers Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Immune Checkpoint Blockers Revenue Market Share by Company (2019-2024)
Table 20. Global Immune Checkpoint Blockers Sale Price by Company (2019-2024) & (USD/Unit)
Table 21. Key Manufacturers Immune Checkpoint Blockers Producing Area Distribution and Sales Area
Table 22. Players Immune Checkpoint Blockers Products Offered
Table 23. Immune Checkpoint Blockers Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Immune Checkpoint Blockers Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Immune Checkpoint Blockers Sales Market Share Geographic Region (2019-2024)
Table 28. Global Immune Checkpoint Blockers Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Immune Checkpoint Blockers Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Immune Checkpoint Blockers Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Immune Checkpoint Blockers Sales Market Share by Country/Region (2019-2024)
Table 32. Global Immune Checkpoint Blockers Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Immune Checkpoint Blockers Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 35. Americas Immune Checkpoint Blockers Sales Market Share by Country (2019-2024)
Table 36. Americas Immune Checkpoint Blockers Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Immune Checkpoint Blockers Revenue Market Share by Country (2019-2024)
Table 38. Americas Immune Checkpoint Blockers Sales by Type (2019-2024) & (K Units)
Table 39. Americas Immune Checkpoint Blockers Sales by Application (2019-2024) & (K Units)
Table 40. APAC Immune Checkpoint Blockers Sales by Region (2019-2024) & (K Units)
Table 41. APAC Immune Checkpoint Blockers Sales Market Share by Region (2019-2024)
Table 42. APAC Immune Checkpoint Blockers Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Immune Checkpoint Blockers Revenue Market Share by Region (2019-2024)
Table 44. APAC Immune Checkpoint Blockers Sales by Type (2019-2024) & (K Units)
Table 45. APAC Immune Checkpoint Blockers Sales by Application (2019-2024) & (K Units)
Table 46. Europe Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 47. Europe Immune Checkpoint Blockers Sales Market Share by Country (2019-2024)
Table 48. Europe Immune Checkpoint Blockers Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Immune Checkpoint Blockers Revenue Market Share by Country (2019-2024)
Table 50. Europe Immune Checkpoint Blockers Sales by Type (2019-2024) & (K Units)
Table 51. Europe Immune Checkpoint Blockers Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Immune Checkpoint Blockers Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Immune Checkpoint Blockers Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Immune Checkpoint Blockers Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Immune Checkpoint Blockers Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Immune Checkpoint Blockers Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Immune Checkpoint Blockers
Table 59. Key Market Challenges & Risks of Immune Checkpoint Blockers
Table 60. Key Industry Trends of Immune Checkpoint Blockers
Table 61. Immune Checkpoint Blockers Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Immune Checkpoint Blockers Distributors List
Table 64. Immune Checkpoint Blockers Customer List
Table 65. Global Immune Checkpoint Blockers Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Immune Checkpoint Blockers Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Immune Checkpoint Blockers Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Immune Checkpoint Blockers Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Immune Checkpoint Blockers Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Immune Checkpoint Blockers Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Immune Checkpoint Blockers Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Immune Checkpoint Blockers Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Immune Checkpoint Blockers Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Immune Checkpoint Blockers Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Immune Checkpoint Blockers Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Immune Checkpoint Blockers Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Immune Checkpoint Blockers Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Immune Checkpoint Blockers Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Bristol Myers Squibb Basic Information, Immune Checkpoint Blockers Manufacturing Base, Sales Area and Its Competitors
Table 80. Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolios and Specifications
Table 81. Bristol Myers Squibb Immune Checkpoint Blockers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Bristol Myers Squibb Main Business
Table 83. Bristol Myers Squibb Latest Developments
Table 84. Merck Basic Information, Immune Checkpoint Blockers Manufacturing Base, Sales Area and Its Competitors
Table 85. Merck Immune Checkpoint Blockers Product Portfolios and Specifications
Table 86. Merck Immune Checkpoint Blockers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Merck Main Business
Table 88. Merck Latest Developments
Table 89. AstraZeneca Basic Information, Immune Checkpoint Blockers Manufacturing Base, Sales Area and Its Competitors
Table 90. AstraZeneca Immune Checkpoint Blockers Product Portfolios and Specifications
Table 91. AstraZeneca Immune Checkpoint Blockers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. AstraZeneca Main Business
Table 93. AstraZeneca Latest Developments
Table 94. Roche Basic Information, Immune Checkpoint Blockers Manufacturing Base, Sales Area and Its Competitors
Table 95. Roche Immune Checkpoint Blockers Product Portfolios and Specifications
Table 96. Roche Immune Checkpoint Blockers Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Roche Main Business
Table 98. Roche Latest Developments
List of


Figure 1. Picture of Immune Checkpoint Blockers
Figure 2. Immune Checkpoint Blockers Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Checkpoint Blockers Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Immune Checkpoint Blockers Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Immune Checkpoint Blockers Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Anti-PD-L1 Drug
Figure 10. Product Picture of Anti-PD-1 Drug
Figure 11. Product Picture of CTLA4
Figure 12. Global Immune Checkpoint Blockers Sales Market Share by Type in 2023
Figure 13. Global Immune Checkpoint Blockers Revenue Market Share by Type (2019-2024)
Figure 14. Immune Checkpoint Blockers Consumed in Lung Cancer
Figure 15. Global Immune Checkpoint Blockers Market: Lung Cancer (2019-2024) & (K Units)
Figure 16. Immune Checkpoint Blockers Consumed in Colorectal Cancer
Figure 17. Global Immune Checkpoint Blockers Market: Colorectal Cancer (2019-2024) & (K Units)
Figure 18. Immune Checkpoint Blockers Consumed in BreastCancer
Figure 19. Global Immune Checkpoint Blockers Market: BreastCancer (2019-2024) & (K Units)
Figure 20. Immune Checkpoint Blockers Consumed in Prostate Cancer
Figure 21. Global Immune Checkpoint Blockers Market: Prostate Cancer (2019-2024) & (K Units)
Figure 22. Immune Checkpoint Blockers Consumed in Melanoma
Figure 23. Global Immune Checkpoint Blockers Market: Melanoma (2019-2024) & (K Units)
Figure 24. Immune Checkpoint Blockers Consumed in Blood Cancers
Figure 25. Global Immune Checkpoint Blockers Market: Blood Cancers (2019-2024) & (K Units)
Figure 26. Global Immune Checkpoint Blockers Sales Market Share by Application (2023)
Figure 27. Global Immune Checkpoint Blockers Revenue Market Share by Application in 2023
Figure 28. Immune Checkpoint Blockers Sales Market by Company in 2023 (K Units)
Figure 29. Global Immune Checkpoint Blockers Sales Market Share by Company in 2023
Figure 30. Immune Checkpoint Blockers Revenue Market by Company in 2023 ($ Million)
Figure 31. Global Immune Checkpoint Blockers Revenue Market Share by Company in 2023
Figure 32. Global Immune Checkpoint Blockers Sales Market Share by Geographic Region (2019-2024)
Figure 33. Global Immune Checkpoint Blockers Revenue Market Share by Geographic Region in 2023
Figure 34. Americas Immune Checkpoint Blockers Sales 2019-2024 (K Units)
Figure 35. Americas Immune Checkpoint Blockers Revenue 2019-2024 ($ Millions)
Figure 36. APAC Immune Checkpoint Blockers Sales 2019-2024 (K Units)
Figure 37. APAC Immune Checkpoint Blockers Revenue 2019-2024 ($ Millions)
Figure 38. Europe Immune Checkpoint Blockers Sales 2019-2024 (K Units)
Figure 39. Europe Immune Checkpoint Blockers Revenue 2019-2024 ($ Millions)
Figure 40. Middle East & Africa Immune Checkpoint Blockers Sales 2019-2024 (K Units)
Figure 41. Middle East & Africa Immune Checkpoint Blockers Revenue 2019-2024 ($ Millions)
Figure 42. Americas Immune Checkpoint Blockers Sales Market Share by Country in 2023
Figure 43. Americas Immune Checkpoint Blockers Revenue Market Share by Country in 2023
Figure 44. Americas Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Figure 45. Americas Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Figure 46. United States Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 47. Canada Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 48. Mexico Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 49. Brazil Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 50. APAC Immune Checkpoint Blockers Sales Market Share by Region in 2023
Figure 51. APAC Immune Checkpoint Blockers Revenue Market Share by Regions in 2023
Figure 52. APAC Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Figure 53. APAC Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Figure 54. China Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 55. Japan Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 56. South Korea Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 57. Southeast Asia Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 58. India Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 59. Australia Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 60. China Taiwan Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 61. Europe Immune Checkpoint Blockers Sales Market Share by Country in 2023
Figure 62. Europe Immune Checkpoint Blockers Revenue Market Share by Country in 2023
Figure 63. Europe Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Figure 64. Europe Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Figure 65. Germany Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 66. France Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 67. UK Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 68. Italy Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 69. Russia Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 70. Middle East & Africa Immune Checkpoint Blockers Sales Market Share by Country in 2023
Figure 71. Middle East & Africa Immune Checkpoint Blockers Revenue Market Share by Country in 2023
Figure 72. Middle East & Africa Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Figure 73. Middle East & Africa Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Figure 74. Egypt Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 75. South Africa Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 76. Israel Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 77. Turkey Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 78. GCC Country Immune Checkpoint Blockers Revenue Growth 2019-2024 ($ Millions)
Figure 79. Manufacturing Cost Structure Analysis of Immune Checkpoint Blockers in 2023
Figure 80. Manufacturing Process Analysis of Immune Checkpoint Blockers
Figure 81. Industry Chain Structure of Immune Checkpoint Blockers
Figure 82. Channels of Distribution
Figure 83. Global Immune Checkpoint Blockers Sales Market Forecast by Region (2025-2030)
Figure 84. Global Immune Checkpoint Blockers Revenue Market Share Forecast by Region (2025-2030)
Figure 85. Global Immune Checkpoint Blockers Sales Market Share Forecast by Type (2025-2030)
Figure 86. Global Immune Checkpoint Blockers Revenue Market Share Forecast by Type (2025-2030)
Figure 87. Global Immune Checkpoint Blockers Sales Market Share Forecast by Application (2025-2030)
Figure 88. Global Immune Checkpoint Blockers Revenue Market Share Forecast by Application (2025-2030)

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (09 May, 2026)
  • Notify To Team (09 May, 2026)
  • Report updation (10 May, 2026)
  • Report Quality Check (10 May, 2026)
  • Report Dispatch (11 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Immune Checkpoint Blockers Market Growth 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.